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Abstract In our consultation practice, it was noted that many
cases that were considered to represent follicular lymphoma
(FL) without a BCL2 translocation were ultimately classified
as nodal marginal zone lymphoma (NMZL). This study set
out to define recurrent morphological features of these cases.
Thirty-three low-grade B cell lymphomas without a BCL2
rearrangement were studied for recurrent morphological fea-
tures. These features were then applied on 20 randomly se-
lected cases to verify if these criteria are able to distinguish
between lymphomas with and without a BCL2 rearrangement,
assigning them to one of five categories ranging from Bcertain
FL^ to Bcertain NMZL.^ Highly recurrent morphological fea-
tures were noted in the lymphomas without a BCL2 rearrange-
ment, which were strongly overlapping with the morphologi-
cal features of NMZL. All six cases that were assigned to the
category of certainly FL or most likely FL indeed harbored a
BCL2 rearrangement, whereas all 12 cases assigned to the
category of most likely NMZL or certain NMZL had no
BCL2 break. Of the two cases in the ambiguous category,
one had received a final diagnosis of FL and the other of
NMZL. This study raises the hypothesis that a subset of
low-grade B cell lymphomas with a follicular growth pattern
but without a BCL2 translocation actually represents NMZL.
This is at present difficult to prove, because no gold standard
is available to differentiate between NMZL and FL without a
BCL2 rearrangement, so further investigations are needed.
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Introduction
Follicular lymphoma (FL) is a low-grade B cell lymphoma
that has a translocation involving BCL2 in up to 90% of cases,
resulting in BCL2 upregulation. It usually has a follicular
growth pattern with expression of germinal center markers
(e.g., CD10 and BCL6). In most cases, a diagnosis of FL is
rather straightforward and can be made by morphology and
immunohistochemistry alone. However, in the absence of
characteristic morphology, typical immunophenotype, or in
the absence of a BCL2 translocation, the diagnosis becomes
more difficult. An important difficulty results from the mor-
phological and immunohistochemical overlap between FL
and nodal marginal zone lymphoma (NMZL) with a
nodular/follicular growth pattern. NMZL is currently defined
as Ba primary nodal B cell neoplasm that morphologically
resembles lymph nodes involved by MZL of extranodal or
splenic types but without evidence of extranodal or splenic
disease^ [1]. The main problem is the lack of positive markers
for NMZL, in fact making this a diagnosis of exclusion.
Previous case reports and small studies indicate that NMZL
may easily be misdiagnosed, especially when there is exten-
sive follicular colonization [2–4]. The follicles that are colo-
nized result in a nodular architecture with partial positivity for
CD10 and BCL6 due to the pre-existent germinal center cells
that are in the same compartment as the tumor cells and
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acquisition of BCL6 expression by the colonizing neoplastic
cells. The colonizing NMZL cells are usually BCL2 positive
which causes the suggestion of BCL2-positive follicles.
In routine diagnostic practice, it was noted that lymphomas
that lack a BCL2 translocation, but display BCL2-positive
follicles at low power, were often considered to represent
FL. However, careful study of BCL2 at high power in these
cases often showed negative cells as a sign of follicular colo-
nization, suggesting a diagnosis of NMZL rather than FL. In
this study, we set out to substantiate the hypothesis that a
subset of lymphomas that are initially classified as FL without
BCL2 translocation (translocation-negative FL), actually rep-
resent NMZL.
Material and methods
Case selection
Fifty-six primary nodal B cell lymphomas, both from in-house
patients (n=21) and consultation cases (n=35), were retrieved
from the archive of the Department of Pathology of the
Radboud University Medical Center (Nijmegen, the
Netherlands). These were selected based on the fact that they
had been tested for a BCL2 translocation by fluorescence in
situ hybridization (FISH) between 2004 and 2010. During this
period, FISHwas used in diagnostic practice in all cases with a
differential diagnostic consideration of FL and NMZL.
Three cases that had originally been classified as NMZL
were excluded because they were considered by the study
group to represent chronic lymphocytic leukemia, diffuse
large B cell lymphoma, and follicular lymphoma grade 3B,
respectively. The study group therefore consisted of 53 cases,
33 without a BCL2 rearrangement and 20 with a BCL2
rearrangement.
Immunohistochemistry
Immunohistochemistry was performed in routine diagnostic
practice according to standard laboratory procedures. Briefly,
4-μm sections were cut from formalin-fixed paraffin-embed-
ded (FFPE) tissue, dried, deparaffinized, rehydrated, and sub-
jected to heat-mediated antigen retrieval. Specific retrieval
procedures for each antigen are indicated in Table 1.
Subsequently, endogenous peroxidase was blocked after
which the primary antibody (Table 1) was applied for 1 h at
room temperature (RT). The secondary antibody
(Powervision poly-HRP-anti MS/Rb/Rt, Immunologic,
Klinipath, Duiven, the Netherlands) was then applied for
30 min at RT after which visualization was performed using
bright 3,3′-diaminobenzidine. Hematoxylin was used as a nu-
clear counterstain.
Fluorescence in situ hybridization
FISH was performed on 4-μm sections from FFPE tissue that
were dried, deparaffinized, rehydrated, and heated for 10 min
in sodium citrate (pH 6.0). Slides were rinsed in 0.01 M hy-
drochloric acid before 15 min of pepsin digestion. After three
rinses of 0.01 M hydrochloric acid and 5 min of fixation in
1% formaldehyde in PBS, sections were dehydrated and dried
after which the probe was added (BCL2 DNA probe, Dako,
Y5407, Glostrup, Denmark; BCL6 DNA probe, Dako,
Y5408, Glostrup Denmark). After 5 min of denaturation at
82 °C, hybridization was performed overnight at 45 °C in a
Dako S2451 hybridizer (Dako). Sections were then
dehydrated, dried, and mounted using medium containing
DAPI as a nuclear counterstain (Vectashield, Vector
Laboratories, Burlingame, CA). Stained sections were
assessed with a Leica DM 4000B fluorescence microscope.
For BCL2 FISH, all cases were evaluated and documented
by the technician (PvC), with subsequent confirmation by one
of the hematopathologists (KH, JvK). FISH for BCL6 was
scored by a single observer (MvdB). Split signals in 20 % of
cells or more were regarded as positive, although in most
positive cases, the amount of positive cells was far above
20 %.
Morphological evaluation
Based on cases lacking a BCL2 translocation, firstly
(immuno)morphological criteria were set for the diagnosis of
NMZL (JVK, OB).
Subsequently, these criteria were applied on 20 of the 53
cases (including 7 cases with and 13 without BCL2 transloca-
tion) by four hematopathologists (JvK, OB, DdJ, KH) at a
multi-headed microscope with all histochemical and immuno-
histochemical stainings but without clinical information or
knowledge of BCL2 translocation status. These cases were
scored on a 5-point scale: certainly FL (1), most likely FL
(2), ambiguous (3), most likely NMZL (4), or certainly
NMZL (5).
Results and discussion
This study followed on the recognition that in consultation
practice, lymphomas that lack a BCL2 translocation, but dis-
play BCL2-positive follicles at low power, may easily be
misdiagnosed as FL. However, after careful evaluation of
H&E morphology and BCL2 immunohistochemical staining
at high power, NMZL could be recognized. From this obser-
vation, we hypothesized that a subset of lymphomas that are
initially classified as translocation-negative FL are actually
better classified as NMZL.
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To investigate this, 53 low-grade B cell lymphomas in the
spectrum of the differential diagnosis of FL and NMZL were
selected. Of these, 20 did show a BCL2 rearrangement with a
FISH split probe and were classified as FL. Thirty-three cases
did not show a BCL2 rearrangement. Table 2 shows the diag-
noses that were made at the time the biopsy was taken and the
final diagnosis, whichwas established during this study, for all
lymphomas lacking a BCL2 translocation.
In a first effort, the morphological features in the
translocation-negative group were evaluated. The following
features were observed to be highly recurrent (Fig. 1): (1)
effaced architecture of the lymph node by a small B cell pro-
liferation with a follicular, marginal zone, or diffuse growth
pattern; (2) centrocytic or BCLL-like^ small cell morphology
with intermingled centroblasts; (3) an immunophenotype of a
mature B cell (CD20 and CD79a positive) with BCL2 posi-
tivity and lacking expression of cyclin D1 and CD5; (4) The
cases with a follicular/ nodular growth pattern showed follic-
ular colonization; the presence of both neoplastic and reactive
cells in a follicle. For the assessment of follicular colonization,
BCL2 and Ki67 immunohistochemistry were carefully evalu-
ated. For BCL2, positive cells (the colonizing lymphoma
cells) could be recognized among negative cells (the pre-
existent cells) at high power. For Ki67, clusters of highly
proliferative cells characterized follicles being colonized,
whereas truly neoplastic follicles were characterized by a rel-
atively low proliferative index. Expression of CD10 in the
BCL2-positive cells was observed only rarely (in 5 out of 21
cases), with mostly weak staining. In 3 out of 16 cases, weak
BCL6 expression was observed in BCL2-positive cells.
The strong overlap between the morphological features in
lymphomas lacking BCL2 rearrangements in this series and
the morphological features of NMZL is in line with our hy-
pothesis that a subset of lymphomas that are initially classified
as translocation-negative FL actually have features of NMZL.
To verify if the criteria defined above were able to recog-
nize lymphomas without a BCL2 rearrangement, they were
applied to 20 cases that were selected randomly from the total
of 53 cases. These 20 cases were reviewed without knowledge
of clinical features or the presence of a BCL2 translocation and
Table 2 Diagnosis of cases
without a BCL2 break Referring center diagnosis Referral center diagnosis Final diagnosis within this study Number
Primary cases (n=13)
NMZL NMZL 9
FL NMZL 4
Referral cases (n=20)
NMZL NMZL NMZL 1
FL NMZL NMZL 7
FL FL NMZL 2
FL/NMZL NMZL NMZL 2
Low-grade B NMZL NMZL 3
Low-grade B FL NMZL 2
Reactive NMZL NMZL 1
Reactive FL 3B NMZL 1
CLL/SLL NMZL NMZL 1
NMZL nodal marginal zone lymphoma, CLL/SLL chronic lymphocytic leukemia/small lymphocytic lymphoma,
FL follicular lymphoma grade 1–2, Low-grade B, low-grade B cell lymphoma, FL 3B follicular lymphoma grade
3B
Table 1 Overview of antibodies
Antigen Manufacturer Dilution Retrieval
BCL2 Dako (clone 124) 1:160 Citrate pH 6.0, 10 min 96 °C
BCL6 Novocastra (Clone LN22) 1:40 Citrate pH 6.0, pressure cooker
CD5 Menarini (Clone 4C7) 1:80 Citrate pH 6.0, 10 min 96 °C
CD10 Monosan (Clone 56C6) 1:20 Citrate pH 6.7, 30 min 100 °C
CD20 Thermo Scientific (Clone L26) 1:300 Citrate pH 6.0, pressure cooker
CD23 Thermo Scientific (Clone 1B12) 1:10 Citrate pH 6.0, 10 min 96 °C
CD79a Dako (Clone JCB117) 1:400 Citrate pH 6.7, 30 min 100 °C
Cyclin D1 Immunologic (Clone SP4) 1:80 Citrate pH 6.7, 30 min 100 °C
Ki-67 Dako (Clone MIB1) 1:200 Citrate pH 6.0, 10 min 96 °C
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assigned to one of five categories ranging from “certain FL” to
Bcertain NMZL,^ as indicated in Table 3. All six cases that
were assigned to the category of certainly FL or most likely
FL indeed harbored a BCL2 rearrangement, whereas all 12
cases assigned to the category of most likely NMZL or certain
NMZL had noBCL2 break. Of the two cases in the ambiguous
category, one had received a final diagnosis of FL and the
other of NMZL.
As indicated in Table 2, many cases (42 %) that received a
final diagnosis of NMZL in this study were at some point
considered to be FL. Only one BCL2 translocation-negative
case was ultimately classified as follicular lymphoma.
Because the morphological criteria for the absence of a BCL2
rearrangement showed strong overlap with the morphological
criteria for NMZL, and because the large majority of
lymphomas without a BCL2 rearrangement were ultimately
diagnosed as NMZL, these results suggest that a subset of
lymphomas that are classified as translocation-negative FL
are actually NMZLs. Although the results are suggestive,
establishing a final proof for this hypothesis is currently very
difficult if not impossible, because specific criteria for NMZL
are lacking. The fact that some lymphomas without a BCL2
rearrangement showed expression of the germinal center
markers CD10 and/or BCL6 is an argument in favor of a diag-
nosis of FL. However, the morphological features outlined
above that were present in these lymphomas argue against this.
Also, expression of CD10 and BCL6 has been reported in
NMZL [2, 5, 6]. In our series, CD10 was positive in the
BCL2-positive cells in 5 out of 21 (24 %) cases, with mostly
weak staining. BCL6 showed weak staining in the BCL2-
positive cells in 3 out of 16 (19 %) cases. The most important
feature to be recognized in this setting is follicular colonization.
We determined the presence of follicular colonization by com-
bining BCL2 and Ki67 staining. Although colonized follicles
seemed to be BCL2-positive on low power examination, at
high power, both BCL2-positive (the colonizing lymphoma
cells) and BCL2-negative (the pre-existent cells) cells were
recognized. A high proliferative index, as indicated by a high
proportion of Ki67-positive cells also characterized follicles
being colonized, whereas truly neoplastic follicles were char-
acterized by a relatively low proliferative index. Finally, in
many cases of FL, the BCL2 expression is stronger than that
of remaining mantle zone B cells and T cells.
FLs without a BCL2 rearrangement might have a rear-
rangement involving BCL6. We studied 22 of the cases with-
out a BCL2 rearrangement for the presence of a rearrangement
involving BCL6, using a dual-color break-apart probe locating
toBCL6. In 5 out of 22 cases (23%), a rearrangement ofBCL6
was identified. Of these 5 cases with a BCL6 rearrangement,
one was weakly positive for CD10, one was positive for CD10
Fig. 1 Morphological features of cases without BCL2 translocation. a–f
Lymph node showing completely effaced architecture with a nodular
appearance on low power (a). On medium power (b), residual follicles
are seen which are BCL2 negative (c) and show a high proliferative index
(d). CD10 (e) is expressed not only in the residual follicles but also in the
surrounding neoplastic cells. BCL2 staining shows blasts without BCL2
expression at high power (f). This case was classified as Bcertainly
NMZL^ based on morphological features. g–j Another lymphoma with
nodular architecture on high power (g). BCL2 immunohistochemistry
shows poorly defined areas with BCL2-negative cells (h). In these
areas, a high proliferative index is present, indicated by frequent Ki-67-
positive cells (i). BCL6 shows diffuse positivity with heterogeneous
intensity (j). This case was classified as Bmost likely NMZL^ based on
morphological features
Table 3 Application of NMZL criteria
Morphological score Number BCL2 break Final diagnosis
n n (%)
1: certainly FL 1 1 FL 1
NMZL 0
2: most likely FL 5 5 FL 5
NMZL 0
3: ambiguous 2 1 FL 1
NMZL 1
4: most likely NMZL 2 0 FL 0
NMZL 2
5: certainly NMZL 10 0 FL 0
NMZL 10
FL follicular lymphoma, NMZL nodal marginal zone lymphoma
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and weakly positive for BCL6, one was weakly positive for
BCL6, and two were negative for both CD10 and BCL6. In
summary, 3 out of 5 (60 %) cases with a BCL6 rearrangement
showed expression either CD10 or BCL6 versus 2 out of 12
(17 %) cases without a BCL6 rearrangement. Although these
results suggest some enrichment for germinal center marker
expression in cases with a BCL6 rearrangement, the difference
between these groups was not statistically significant (p=
0.117 with Fisher’s exact test). This finding is of potential
interest, but a definitive conclusion would require the study
of additional cases.
Cases were included in this study when they had been
tested for a BCL2 translocation with FISH. In general, BCL2
FISH is not performed on cases that are considered to be
straightforward FL by morphology and immunohistochemis-
try, resulting in a bias toward atypical cases in our study. This
also means that the group of Bstraightforward^ FLs, that was
not included in this study, might contain BCL2 translocation-
negative cases, and we therefore cannot make any conclusions
on the frequency of BCL2 translocation-negative FL.
However, our study does suggest that a proportion of lympho-
mas regarded as BCL2 translocation-negative FL are in fact
NMZLs. Because NMZL is often a diagnosis of exclusion,
this suggestion is currently hard to prove. However, previous
studies suggest that BCL2 translocation-negative FLs are ge-
netically different from FLs with a BCL2 translocation and
have at least some features of NMZL. One study reported
specific features of MUM1-positive and CD10-negative fol-
licular lymphomas, including a frequent lack of BCL2 trans-
locations [4]. The combination of CD10 negativity and
MUM1 positivity, both features of NMZL, and the lack of
BCL2 translocations suggest that this series might very well
include NMZLs. A comparative genomic hybridization and
gene expression study in BCL2 translocation-negative FLs
demonstrated less frequent expression of CD10 and enriched
NF-κB signatures, both features of NMZL [7]. This suggests
that (some of) these cases really are NMZLs, although the
authors raise arguments against this, including strong BCL6
expression in all cases. We have however convincing data that
NMZL cells can acquire BCL6 expression upon entering the
follicular dendritic cell environment (manuscript in prepara-
tion). In a more recent comparative genomic hybridization
study, translocation-negative FL showed aberrations that clus-
tered more with NMZL than with FL with a BCL2 transloca-
tion [8].
To finally resolve these issues, a positive marker for NMZL
is highly needed. In addition to proposed new immunohisto-
chemical markers for NMZL [9–11], better insight into its
pathogenesis is essential for its proper classification. Here, a
complicating factor is the fact that NMZL is often a diagnosis
of exclusion, and therefore we cannot be sure that it represents
a single entity. This possible heterogeneity might also be an
impediment for studies into the pathogenesis of NMZL.
In conclusion, we have established immunomorphological
characteristics of a group of low-grade B cell lymphomas that
lacked a BCL2 translocation. These criteria largely overlapped
with the features of NMZL, and we propose that a subset of
lymphomas that is currently often classified as FL without a
BCL2 translocation is actually better classified as NMZL.
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